Page 2585 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 158 Hematologic Aspects of Parasitic Diseases 2303.e5

197. Bailey JW, Smith DH: The use of the acridine orange QBC technique 220. Marin-Neto JA, Cunha-Neto E, Maciel BC, et al: Pathogenesis of
in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg chronic Chagas heart disease. Circulation 115:1109, 2007.
86:630, 1992. 221. Freilij H, Altcheh J: Congenital Chagas’ disease: diagnostic and clinical
198. Lumsden WH, Kimber CD, Evans DA, et al: Trypanosoma brucei: aspects. Clin Infect Dis 21:551, 1995.
miniature anion-exchange centrifugation technique for detection of 222. Miles MA: Culturing and biological cloning of Trypanosoma cruzi.
low parasitaemias: adaptation for field use. Trans R Soc Trop Med Hyg Methods Mol Biol 21:15, 1993.
73:312, 1979. 223. Luz ZM, Coutinho MG, Cancado JR, et al: Hemoculture: sensitive
199. Deborggraeve S, Lejon V, Ekangu RA, et al: Diagnostic accuracy technique in the detection of Trypanosoma cruzi in chagasic patients
of PCR in gambiense sleeping sickness diagnosis, staging and post- in the chronic phase of Chagas disease. Rev Soc Bras Med Trop 27:143,
treatment follow-up: a 2-year longitudinal study. PLoS Negl Trop Dis 1994.
5:e972, 2011. 224. Gomes YM: PCR and sero-diagnosis of chronic Chagas’ disease:
200. Cattand P, Miezan BT, de Raadt P: Human African trypanosomiasis: biotechnological advances. Appl Biochem Biotechnol 66:107, 1997.
use of double centrifugation of cerebrospinal fluid to detect trypano- 225. Russomando G, Sánchez Z, Meza G, et al: Shed acute-phase antigen
somes. Bull World Health Organ 66:83, 1988. protein in an ELISA system for unequivocal diagnosis of congenital
201. Chappuis F, Loutan L, Simarro P, et al: Options for field diagnosis of Chagas disease. Expert Rev Mol Diagn 10:705, 2010.
human African trypanosomiasis. Clin Microbiol Rev 18:133, 2005. 226. Brasil PE, Castro R, Castro L: Commercial enzyme-linked immu-
202. Magnus E, Vervoort T, Van Meirvenne N: A card-agglutination test nosorbent assay versuspolymerase chain reaction for the diagnosis of
with stained trypanosomes (C.A.T.T.) for the serological diagnosis of chronic Chagas disease: a systematic review and meta-analysis. Mem
T. b. gambiense trypanosomiasis. Ann Soc Belg Med Trop 58:169, 1978. Inst Oswaldo Cruz 111:1–19, 2016.
203. Pansaerts R, Van Meirvenne N, Magnus E, et al: Increased sensitivity 227. Bern C: Antitrypanosomal therapy for chronic Chagas’ disease. N Engl
of the card agglutination test CATT/Trypanosoma brucei gambiense by J Med 364:2527, 2011.
inhibition of complement. Acta Trop 70:349, 1998. 228. Malik LH, Singh GD, Amsterdam EA: The epidemiology, clinical
204. Nantulya VM: TrypTect CIATT—a card indirect agglutination try- manifestations, and management of Chagas heart disease. Clin Cardiol
panosomiasis test for diagnosis of Trypanosoma brucei gambiense and T. 9:565, 2015.
b. rhodesiense infections. Trans R Soc Trop Med Hyg 91:551, 1997. 229. Soriano-Arandes A, Angheben A, Serre-Delcor N, et al: Control and
205. Buscher P, Lejon V, Magnus E, et al: Improved latex agglutination management of congenital Chagas disease in Europe and other non-
test for detection of antibodies in serum and cerebrospinal fluid of endemic countries: current policies and practices. Trop Med Int Health
Trypanosoma brucei gambiense infected patients. Acta Trop 73:11, 5:590–596, 2016.
1999. 230. Castro JA, de Mecca MM, Bartel LC: Toxic side effects of drugs used
206. Lejon V, Buscher P, Sema NH, et al: Human African trypanosomiasis: a to treat Chagas’ disease (American trypanosomiasis). Hum Exp Toxicol
latex agglutination field test for quantifying IgM in cerebrospinal fluid. 25:471, 2006.
Bull World Health Organ 76:553, 1998. 231. Gudino MD, Linares J: Chagas’ disease and blood transfusion, Arlington,
207. Steinmann P, Stone CM, Sutherland CS, et al: Contemporary and VA, 1990, American Association of Blood Banks.
emerging strategies for eliminating human African trypanosomiasis 232. Schmunis GA: Prevention of transfusional Trypanosoma cruzi infection
due to Trypanosoma brucei gambiense: review. Trop Med Int Health in Latin America. Mem Inst Oswaldo Cruz 94:93, 1999.
6:707–718, 2015. 233. Schmunis GA, Zicker F, Cruz JR, et al: Safety of blood supply for
208. Pepin J, Milord F, Guern C, et al: Difluoromethylornithine for arseno- infectious diseases in Latin American countries, 1994-1997. Am J Trop
resistant Trypanosoma brucei gambiense sleeping sickness. Lancet 2:1431, Med Hyg 65:924, 2001.
1987. 234. Guhl F, Lazdins-Helds JK, editors: Reporte del grupo de trabajo científico
209. Pepin J, Milord F, Khonde AN, et al: Risk factors for encepha- sobre la enfermedad de Chagas, Geneva, 2007, World Health Organiza-
lopathy and mortality during melarsoprol treatment of Trypanosoma tion. <http://www.who.int/tdr/publications/tdr-research-publications/
brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 89:92, reporte-enfermedad-chagas/en/index.html>.
1995. 235. Oelemann WM, Vanderborght BO, Verissimo Da Costa GC, et al:
210. Pepin J, Milord F, Guern C, et al: Trial of prednisolone for prevention A recombinant peptide antigen line immunoassay optimized for the
of melarsoprol-induced encephalopathy in gambiense sleeping sickness. confirmation of Chagas’ disease. Transfusion 39:711, 1999.
Lancet 1:1246, 1989. 236. Umezawa ES, Bastos SF, Coura JR, et al: An improved serodiagnostic
211. Pepin J, Milord F, Khonde A, et al: Gambiense trypanosomiasis: test for Chagas’ disease employing a mixture of Trypanosoma cruzi
frequency of, and risk factors for, failure of melarsoprol therapy. Trans recombinant antigens. Transfusion 43:91, 2003.
R Soc Trop Med Hyg 88:447, 1994. 237. Bern C, Kjos S, Yabsley MJ, et al: Trypanosoma cruzi and Chagas’
212. Babokhov P, Sanyaolu AO, Oyibo WA, et al: A current analysis of disease in the United States. Clin Microbiol Rev 24:655–681, 2011.
chemotherapy strategies for the treatment of human African trypano- 238. Wendel S: Transfusion transmitted Chagas disease: is it really under
somiasis. Pathog Glob Health 5:242–252, 2013. control? Acta Trop 115:28, 2010.
213. Coura JR, Borges-Pereira J: Chagas disease: 100 years after its discovery. 239. Van Voorhis WC, Barrett LK, Eastman RT, et al: Trypanosoma cruzi
A systemic review. Acta Trop 115:5, 2010. inactivation in human platelet concentrates and plasma by a psoralen
214. Basile L, Jansá JM, Carlier Y: Chagas disease in European countries: (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Che-
the challenge of a surveillance system. Euro Surveill 16(37):19968, mother 47:475, 2003.
2011. 240. Chagas disease found in three organ transplant recipients—Priorities
215. Gaunt M, Miles M: The ecotopes and evolution of triatomine bugs for testing blood donors? e-Network Forum, California Blood Bank
(Triatominae) and their associated trypanosomes. Mem Inst Oswaldo Society, posted March 29, 2002. <http://www.cbbsweb.org/enf/2002/
Cruz 95:557, 2000. chagasorgnrecip.html>.
216. El-Sayed NM, Myler PJ, Bartholomeu DC, et al: The genome sequence 241. Chagas disease after organ transplantation—United States, 2001.
of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 309:409, MMWR Morb Mortal Wkly Rep 51:210, 2002.
2005. 242. Grant IH, Gold JW, Wittner M, et al: Transfusion-associated acute
217. El-Sayed NM, Myler PJ, Blandin G, et al: Comparative genomics of Chagas disease acquired in the United States. Ann Intern Med 111:849,
trypanosomatid parasitic protozoa. Science 309:404, 2005. 1989.
218. Vallejo GA, Chiari E, Macedo AM, et al: A simple laboratory method 243. Nickerson P, Orr P, Schroeder ML, et al: Transfusion-associated
for distinguishing between Trypanosoma cruzi and Trypanosoma rangeli. Trypanosoma cruzi infection in a non-endemic area. Ann Intern Med
Trans R Soc Trop Med Hyg 87:165, 1993. 111:851, 1989.
219. Dutra WO, Menezes CA, Magalhães LM, et al: Immunoregulatory 244. Cimo PL, Luper WE, Scouros MA: Transfusion-associated Chagas’
networks in human Chagas disease. Parasite Immunol 36:377, 2014. disease in Texas: report of a case. Tex Med 89:48, 1993.